Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Approvals Action
New registrations for seizures and HIV

Posted 21 February 2021 AM

Eisai has registered a new formulation of its PBS-listed seizure treatment Fycompa. The new version of the medication can be taken via oral suspension, rather than tablets. 

It joined HIV specialist ViiV's Vocabris tablets as an addition to the ARTG during the week. This medicine is indicated for short term use with Janssen's Edurant oral lead in to assess tolerability of cabotegravir prior to administration of cabotegravir prolonged-release suspension for injection plus rilpivirine prolonged-release suspension for injection.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas